AMG 811

Drug Profile

AMG 811

Alternative Names: AMG-811

Latest Information Update: 16 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus
  • Discontinued Discoid lupus erythematosus; Psoriasis

Most Recent Events

  • 16 Oct 2015 Discontinued - Phase-I for Psoriasis in Australia and New Zealand (SC)
  • 01 Aug 2014 Amgen completes a phase Ib trial in Systemic lupus erythematosus in USA, France, Hong Kong, Malaysia and Mexico (NCT00818948)
  • 31 Oct 2012 Amgen completes a phase I trial in Psoriasis in Australia and New Zealand (NCT01510951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top